These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29432571)

  • 1. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo.
    Hassler MR; Turanov AA; Alterman JF; Haraszti RA; Coles AH; Osborn MF; Echeverria D; Nikan M; Salomon WE; Roux L; Godinho BMDC; Davis SM; Morrissey DV; Zamore PD; Karumanchi SA; Moore MJ; Aronin N; Khvorova A
    Nucleic Acids Res; 2018 Mar; 46(5):2185-2196. PubMed ID: 29432571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs.
    Shmushkovich T; Monopoli KR; Homsy D; Leyfer D; Betancur-Boissel M; Khvorova A; Wolfson AD
    Nucleic Acids Res; 2018 Nov; 46(20):10905-10916. PubMed ID: 30169779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.
    Biscans A; Coles A; Echeverria D; Khvorova A
    J Control Release; 2019 May; 302():116-125. PubMed ID: 30940496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA conjugate delivery systems.
    Jeong JH; Mok H; Oh YK; Park TG
    Bioconjug Chem; 2009 Jan; 20(1):5-14. PubMed ID: 19053311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic siRNAs and non-viral systems for their delivery].
    Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
    Mol Biol (Mosk); 2012; 46(3):371-86. PubMed ID: 22888628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo.
    Biscans A; Coles A; Haraszti R; Echeverria D; Hassler M; Osborn M; Khvorova A
    Nucleic Acids Res; 2019 Feb; 47(3):1082-1096. PubMed ID: 30544191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Types of non-viral delivery systems of small interfering RNA].
    Glebova KV; Marakhonov AV; Baranova AV; Skoblov MIu
    Mol Biol (Mosk); 2012; 46(3):387-401. PubMed ID: 22888629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery systems of small interfering RNA by systemic administration.
    Kawakami S; Hashida M
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I.
    Kim SI; Shin D; Choi TH; Lee JC; Cheon GJ; Kim KY; Park M; Kim M
    Mol Ther; 2007 Jun; 15(6):1145-52. PubMed ID: 17440441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways.
    Osborn MF; Coles AH; Biscans A; Haraszti RA; Roux L; Davis S; Ly S; Echeverria D; Hassler MR; Godinho BMDC; Nikan M; Khvorova A
    Nucleic Acids Res; 2019 Feb; 47(3):1070-1081. PubMed ID: 30535404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo.
    Biscans A; Ly S; McHugh N; Cooper DA; Khvorova A
    J Control Release; 2022 Sep; 349():831-843. PubMed ID: 35917865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW; Davis ME
    Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.
    Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF
    Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.
    Haraszti RA; Roux L; Coles AH; Turanov AA; Alterman JF; Echeverria D; Godinho BMDC; Aronin N; Khvorova A
    Nucleic Acids Res; 2017 Jul; 45(13):7581-7592. PubMed ID: 28591791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi therapeutics: an update on delivery.
    Nguyen T; Menocal EM; Harborth J; Fruehauf JH
    Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.